UCL Human Model Shows sEH Inhibitor GSK2256294 Cuts Intermediate Monocytes via Epoxy-Oxylipin Rise

Researchers ran a two-arm randomized study at UCL using intradermal UV-killed E. coli to induce controlled, self-resolving inflammation. The prophylactic arm dosed 12 treated and 12 placebo volunteers two hours before challenge; the therapeutic arm dosed another 24 volunteers four hours after. Both arms showed that blocking soluble epoxide hydrolase preserved 12,13-EpOME, which in turn inhibited p38 MAPK phosphorylation and limited the conversion of classical to intermediate monocytes in blood and tissue.

The work extends prior mouse data on epoxy-oxylipins into humans and directly links a measurable immune-cell shift to faster symptom resolution. It also explains why visible signs lagged behind cellular changes, highlighting a disconnect between macroscopic inflammation scores and the monocyte phenotype that drives chronic disease progression.

If replicated in patients, the pathway offers a druggable brake distinct from broad cytokine blockers. Next steps require dose-finding and safety data in rheumatoid arthritis or metabolic-disease cohorts where intermediate monocytes are already elevated.